Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
The Column Group (TCG) is a venture capital firm founded in 2007 and based in San Francisco, California. It focuses on the life sciences sector, particularly biotechnology and therapeutics, with a portfolio of 55 companies and 18 successful exits. TCG operates through various funds, including TCG Platform funds and TCG Crossover (TCGX).
TCG invests in early technology platforms, single assets, and later-stage programs in the life sciences sector. Their check sizes vary across pre-seed to Series C stages, emphasizing biotechnology and therapeutics. The firm employs an edge-to-edge investment model, supporting companies from inception through exit.
Notable companies in TCG's portfolio include Carmot Therapeutics, acquired by Roche for $3.3 billion; Peloton Therapeutics, acquired by Merck for up to $2.35 billion; and Constellation Pharmaceuticals, acquired by MorphoSys for $1.7 billion. Other significant exits include Aragon Pharmaceuticals and Seragon Pharmaceuticals.
Email info@thecolumngroup.com with your deck to pitch TCG.
Yes, TCG often leads investment rounds, particularly in early-stage biotechnology companies.
TCG is open to follow-on investments, especially for companies that demonstrate significant progress and potential for growth.
TCG manages multiple funds, but specific fund sizes are not publicly disclosed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.